Neurology and Psychiatry (CNS)

PRA is an industry leader providing innovative solutions for CNS. Our work spans from early phase development to NDA and MAA submissions, and we have developed a thorough understanding of the operational considerations for studies in all major CNS indications.

PRA has contributed to the successful market approvals of 19 CNS drugs in a number of indications: ADHD, Parkinson’s disease, cervical dystonia, epilepsy, migraine, pain, arthritis and relapsing-remitting multiple sclerosis.

In the past five years, we have conducted over 530 Phase I-IV clinical trials involving over 8,670 sites and 66,500+ subjects and provided consulting services for more than 140 projects.

Key Areas of CNS Expertise

The following table summarizes our recent CNS study experience in our top indications.


CNS Number of Clinical Studies Number of Clinical Sites Number of Clinical Patients
Epilepsy 37 2,220+ 6,680+
Chronic Pain 39 410+ 3,375+
Alzheimer’s Disease 29 745+ 5,585+
Multiple Sclerosis 33 1,870+ 12,100+
Parkinson’s Disease 24 570+ 2,690+
ADD/ADHD 32 525+ 3,425+
Depression 19 130+ 720+
Schizophrenia 99 350+ 14,485+
Total 312 6,820+ 49,060+


  • Dedicated CNS start-up unit for efficient global study activation
  • Novel database analytics facilitate strategic country and site selection
  • Proactive strategies to motivate sites and promote patient recruitment in highly competitive indications such as multiple sclerosis and Alzheimer’s disease
  • Integrated project management by a skilled global team with significant CNS experience
  • Standardized diagnosis and assessment with special attention to rating, a critical part of most CNS studies